Indian Patent Office rejects Sovaldi patent, paves way for generics
16-01-2015
Robert Kneschke / Shutterstock.com
US biotechnology company Gilead has agreed a licensing deal with seven Indian drug makers that will enable them to sell a generic version of a drug used to treat hepatitis C.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Gilead, patent, licensing, Sovaldi, generics
